The REMAP-CAP (N = 1549) and Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients (COVID-PACT, N = 292) trials failed to demonstrate benefit with ASA or P2Y12 inhibitors alone [18,32]. Here, P2RY12 is linked to COVID-19.